Coronary Artery Calcium Scoring: Implications for Lipoprotein(a) and ASCVD Risk

Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide, making effective risk assessment crucial for prevention strategies. One emerging tool in this domain is coronary artery calcium (CAC) scoring, which quantifies calcified plaque in the coronary arteries. Recent research has raised questions about the utility of CAC scoring in individuals with elevated lipoprotein(a) [Lp(a)], a lipoprotein associated with atherosclerotic cardiovascular disease (ASCVD) risk. Given that Lp(a) is linked to non-calcified plaque, understanding its interaction with CAC scoring is essential for accurate risk assessment. In a pooled analysis of 11,319 participants from four U.S.-based prospective cohort studies, researchers investigated the relationship between elevated Lp(a) levels (defined as >50 mg/dL) and CAC scores. Over a mean follow-up period of 14.8 years, the study found that both elevated Lp(a) and CAC scores greater than zero were independently associated with an increased risk of ASCVD events, such as myocardial infarction and stroke. Specifically, individuals with Lp(a) >50 mg/dL had a hazard ratio (HR) of 1.24 (95% CI: 1.09-1.41) for ASCVD, while those with CAC >0 had an HR of 2.44 (95% CI: 2.14-2.77). Notably, among participants with CAC = 0, the incidence of ASCVD was still higher in those with elevated Lp(a) compared to those with lower levels (4.9 vs 3.8 events per 1,000 person-years, HR: 1.28; 95% CI: 1.01-1.60). The implications of these findings are significant for individuals concerned about their cardiovascular health. Regular monitoring of both Lp(a) and CAC scores can provide a more comprehensive picture of ASCVD risk, especially in those with elevated Lp(a). For patients with CAC = 0, while the absolute event rates remain low, the increased relative risk associated with high Lp(a) levels suggests that these individuals may still benefit from lifestyle modifications and preventive measures. This could include dietary changes, increased physical activity, and potentially pharmacological interventions aimed at lowering Lp(a) levels. In terms of biomarkers, this study highlights the importance of measuring Lp(a) and CAC in assessing cardiovascular risk. At Metabolicum.org, we provide calculators that can help users evaluate their Lp(a) levels and understand their implications for metabolic health. Monitoring these biomarkers can aid in early detection and intervention strategies for those at risk of ASCVD. In conclusion, the study underscores the relevance of CAC scoring in individuals with elevated Lp(a) for ASCVD risk assessment. While elevated Lp(a) is associated with increased risk across CAC strata, including those with CAC = 0, the overall event rates remain low. Therefore, individuals should be proactive in monitoring these biomarkers and discussing their cardiovascular risk with healthcare providers to implement effective prevention strategies.